We were honored to receive an invitation to speak, together with Amazon Web Services (AWS) Scientific Computing and Regeneron Genetics Center, at the 2014 AWS re:Invent conference being held next week in Las Vegas. As a member of the AWS Partner Network Life Science Competency Program, we work with AWS to provide genomic analysis and data management solutions for biopharma, diagnostic test providers, genome research centers, and sequencing service providers.
By combining DNAnexus vertical market expertise with AWS’s cloud computing technology we deliver an enterprise-grade solution for genome informatics and data management. We recently announced that the DNAnexus platform is powering novel collaborations between the Regeneron Genetics Center and leading healthcare providers. Jeffrey Reid, PhD, head of genome informatics at the RGC will be discussing in detail how the RGC is using the DNAnexus platform to integrate sequencing data with de-identified clinical records from healthcare partners. To date, the RGC has sequenced samples from more than 10,000 individuals and operating at a capacity to sequence more than 50,000 samples per year.
HLS303 – How Cloud Computing is Redefining Research: Secure, Collaborative Science at Scale
5:30 PM, Thursday, November 13th, Venetian Delfino Room (4002)
Jeffrey Reid, PhD – Director and Head of Genome Informatics, Regeneron Genetics Center
Omar Serang – Chief Cloud Officer, DNAnexus
Angel Pizarro – Technical Business Development Manager, Amazon Web Services
DNAnexus delivers out-of-the-box job features in support of genomic research and collaboration, providing an extensive list of value-adds on top of AWS, including:
- Large-scale job control, supporting workflows using 1000s of nodes
- High-performance storage framework to serve large objects to 1000s of nodes
- Resource consumption tracking and alerts to avoid invoice surprises
- Application level identity and access management for secure sharing of data and tools globally
The DNAnexus platform is employed by organizations and consortia globally to integrate data, enable collaboration, and accelerate discovery, and has been used to investigate conditions such as cardiovascular disease, cancer, and Alzheimer disease. You can learn more about DNAnexus-supported initiatives here and here.